Search





Search





Markets
/
Stocks
/
nasdaq-vcyt
/

Veracyte Inc

VCYT

Add to Watchlist

38.480USD

-0.420-1.08%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

3.07BMarket Cap

34.51P/E TTM



Veracyte Inc

38.480

-0.420-1.08%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Veracyte Inc

Currency: USD Updated: 2026-05-15

Key Insights

Veracyte Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 6 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 47.82.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Veracyte Inc's Score

Industry at a Glance

Industry Ranking

6 / 382

Overall Ranking

52 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Veracyte Inc Highlights

StrengthsRisks

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 43.23% year-on-year.

Fairly Valued

The company’s latest PE is 34.51, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 96.10M shares, decreasing 1.93% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 20.77K shares of this stock.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

47.818

Target Price

+25.01%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Veracyte Inc is 9.28, ranking 5 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 139.07M, representing a year-over-year increase of 21.49%, while its net profit experienced a year-over-year increase of 307.36%.

Score

Industry at a Glance

Previous score

9.28

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.68

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.71

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Veracyte Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Veracyte Inc is 5.61, ranking 363 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is 34.51, which is 323.63% below the recent high of 146.20 and 1031.37% above the recent low of -321.44.

Score

Industry at a Glance

Previous score

5.61

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 6/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Veracyte Inc is 8.15, ranking 157 out of 382 in the Biotechnology & Medical Research industry. The average price target is 48.00, with a high of 57.00 and a low of 43.00.

Score

Industry at a Glance

Previous score

8.46

Change

-0.31

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

47.818

Target Price

+22.93%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Veracyte Inc

VCYT

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Veracyte Inc is 9.17, ranking 25 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 43.33 and the support level at 32.39, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.21

Change

-0.04

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.687

Buy

RSI(14)

59.810

Neutral

STOCH(KDJ)(9,3,3)

66.051

Neutral

ATR(14)

2.198

High Vlolatility

CCI(14)

38.932

Neutral

Williams %R

33.090

Buy

TRIX(12,20)

0.787

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

38.978

Sell

MA10

38.368

Buy

MA20

35.845

Buy

MA50

33.866

Buy

MA100

36.653

Buy

MA200

36.239

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Veracyte Inc is 10.00, ranking 1 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 120.44%, representing a quarter-over-quarter increase of 6.15%. The largest institutional shareholder is Catherine Wood, holding a total of 3.05M shares, representing 3.83% of shares outstanding, with 23.92% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

11.51M

+1.72%

Artisan Partners Limited Partnership

6.26M

-15.03%

State Street Investment Management (US)

4.36M

+3.84%

Fidelity Management & Research Company LLC

4.88M

-15.13%

ARK Investment Management LLC

Star Investors

3.89M

-12.95%

Dimensional Fund Advisors, L.P.

2.80M

-10.19%

Wellington Management Company, LLP

2.04M

-39.63%

Geode Capital Management, L.L.C.

1.90M

+0.50%

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Veracyte Inc is 5.68, ranking 40 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.90. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.